BioCentury | Jun 29, 2009
Clinical News

P1A: Phase I data

...3 subjects in the 28 mg arm and 6 subjects in the placebo arm (p<0.05). Ipsat Therapies Ltd....
BioCentury | Oct 29, 2007
Clinical News

P1A: Phase IIb data

...Also, 12.7% of P1A patients had ampicillin-resistant coliforms vs. 40.2% of placebo patients (p< 0.001). Ipsat Therapies Ltd....
BioCentury | Dec 11, 2006
Clinical News

P1A: Phase IIb started

...upper- and lower-respiratory tract infections. Patients will receive P1A plus penicillin or penicillin plus placebo. Ipsat Therapies Ltd....
BioCentury | Jan 30, 2006
Company News

Ipsat Therapies board of directors update

Ipsat Therapies Ltd. , Helsinki, Finland Business: Infectious Appointed: Ulf Tossman, investment director at InnovationsKapital WIR Staff Infectious...
BioCentury | Apr 18, 2005
Company News

Ipsat Therapies board of directors update

Ipsat Therapies Ltd. , Helsinki, Finland Business: Infectious Appointed: Wolfgang Pieken, CEO of MWG Biotech AG, as chairman; Aki Prihti, investment director of Bio Fund; Riitta Jaaskelainen, investment director of Finnish Industry Investment Ltd.; Pauli Marttila,...
BioCentury | Apr 11, 2005
Product Development

Not bound to onercept

...development of bacterial resistance reduces the utility of many antibiotics, especially in hospital-acquired infections (HAIs). Ipsat Therapies...
BioCentury | Apr 11, 2005
Clinical News

P1A: Phase IIa data

...were presented at the European Congress on Clinical Microbiology and Infectious Diseases meeting in Copenhagen. Ipsat Therapies Ltd....
BioCentury | Oct 20, 2003
Clinical News

P1A: Phase I

...was safe and removed excess non-absorbed ampicillin to levels below detection limits in the gut. Ipsat Therapies...
BioCentury | Sep 23, 2002
Company News

Ipsat Therapies Oy, Tripep deal

...invested E5.5 million ($5.1 million) in Ipsat for a 30% stake (see BioCentury, June 17). Ipsat Therapies...
BioCentury | Jun 17, 2002
Finance

Ebb & Flow

...back every third share for SEK15 and that it intends to start merger negotiations with Ipsat Therapies...
Items per page:
1 - 10 of 14
BioCentury | Jun 29, 2009
Clinical News

P1A: Phase I data

...3 subjects in the 28 mg arm and 6 subjects in the placebo arm (p<0.05). Ipsat Therapies Ltd....
BioCentury | Oct 29, 2007
Clinical News

P1A: Phase IIb data

...Also, 12.7% of P1A patients had ampicillin-resistant coliforms vs. 40.2% of placebo patients (p< 0.001). Ipsat Therapies Ltd....
BioCentury | Dec 11, 2006
Clinical News

P1A: Phase IIb started

...upper- and lower-respiratory tract infections. Patients will receive P1A plus penicillin or penicillin plus placebo. Ipsat Therapies Ltd....
BioCentury | Jan 30, 2006
Company News

Ipsat Therapies board of directors update

Ipsat Therapies Ltd. , Helsinki, Finland Business: Infectious Appointed: Ulf Tossman, investment director at InnovationsKapital WIR Staff Infectious...
BioCentury | Apr 18, 2005
Company News

Ipsat Therapies board of directors update

Ipsat Therapies Ltd. , Helsinki, Finland Business: Infectious Appointed: Wolfgang Pieken, CEO of MWG Biotech AG, as chairman; Aki Prihti, investment director of Bio Fund; Riitta Jaaskelainen, investment director of Finnish Industry Investment Ltd.; Pauli Marttila,...
BioCentury | Apr 11, 2005
Product Development

Not bound to onercept

...development of bacterial resistance reduces the utility of many antibiotics, especially in hospital-acquired infections (HAIs). Ipsat Therapies...
BioCentury | Apr 11, 2005
Clinical News

P1A: Phase IIa data

...were presented at the European Congress on Clinical Microbiology and Infectious Diseases meeting in Copenhagen. Ipsat Therapies Ltd....
BioCentury | Oct 20, 2003
Clinical News

P1A: Phase I

...was safe and removed excess non-absorbed ampicillin to levels below detection limits in the gut. Ipsat Therapies...
BioCentury | Sep 23, 2002
Company News

Ipsat Therapies Oy, Tripep deal

...invested E5.5 million ($5.1 million) in Ipsat for a 30% stake (see BioCentury, June 17). Ipsat Therapies...
BioCentury | Jun 17, 2002
Finance

Ebb & Flow

...back every third share for SEK15 and that it intends to start merger negotiations with Ipsat Therapies...
Items per page:
1 - 10 of 14